鏈接：https://www.abinscience.cn/product/71/27542.html
名稱：Research Grade Retatrutide
貨號：SW328046
種屬反應(yīng)性：Human
應(yīng)用：ELISA, Functional assay, Research in vivo
同種型：Biosynthetic peptide.
種屬：Human
克隆類型：Monoclonal
靶標(biāo)：GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R, Gastric inhibitory polypeptide receptor, GIPR, GIP-R, Glucose-dependent insulinotropic polypeptide receptor, GCGR, Glucagon receptor, GL-R
內(nèi)毒素水平：Please contact with the lab for this information.
純度：>95% as determined by HPLC.
純化方式：Purified by HPLC.
Accession號：P43220 & P48546 & P47871
狀態(tài)：Liquid
產(chǎn)品使用信息：應(yīng)用方法ELISA ；稀釋比例1:2000-1:20000
用途范圍：僅用于科研
儲存：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
?
產(chǎn)品介紹：Research Grade Retatrutide (LY3437943)｜SW328046 是艾必賽生物（abinScience）推出的研究級三重代謝受體激動劑對照試劑，屬藥物對照品類，可特異性激活人源GIPR、GLP-1R、GCGR三個靶點(diǎn)，適用于ELISA（標(biāo)準(zhǔn)品/包被原）、功能性實(shí)驗(yàn)（受體活性驗(yàn)證、細(xì)胞藥效初篩）、科研體內(nèi)（代謝疾病模型藥效/藥代研究）場景。該產(chǎn)品為生物合成多肽，經(jīng)HPLC純化，純度>95%（HPLC），以液體形式保存于0.01M PBS（pH 7.4）中；短期2-8°C使用，長期建議-20°C至-80°C保存12個月，避免反復(fù)凍融。（RUO，僅限科研/非臨床用途）
Retatrutide是禮來（Eli Lilly）在研的長效三靶激素受體激動劑（研發(fā)代號LY3437943），為修飾多肽類藥物，可同時激活葡萄糖依賴性促胰島素多肽（GIP）、胰高血糖素樣肽-1（GLP-1）、胰高血糖素三條通路，協(xié)同調(diào)控血糖、抑制攝食、促進(jìn)脂肪分解，臨床開發(fā)方向覆蓋肥胖、2型糖尿病、非酒精性脂肪性肝炎（NASH）等代謝性疾病，目前披露的II/III期數(shù)據(jù)表現(xiàn)優(yōu)于已上市的GLP-1單靶、GLP-1/GIP雙靶同類藥物。其作用的三個受體均為代謝領(lǐng)域核心熱門靶點(diǎn)，該研究級Retatrutide可作為藥物研發(fā)過程中的陽性對照、質(zhì)控參照、PK/PD標(biāo)準(zhǔn)品，也適用于靶點(diǎn)機(jī)制研究、競品篩選等科研場景。
?
?
?
?
產(chǎn)品購買聯(lián)系方式：027-87433958/17302791434
郵箱：info@abinscience.com
參考文獻(xiàn)：
Retatrutide-A Game Changer in Obesity Pharmacotherapy. PMID: 40563436
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. PMID: 37366315
The power of three: Retatrutide's role in modern obesity and diabetes therapy. PMID: 39515565
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. PMID: 37385280
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. PMID: 38858523
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. PMID: 39318607
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. PMID: 40291085
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. PMID: 40609566
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. PMID: 40728138
Retatrutide. PMID: 39429457
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. PMID: 42250575
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. PMID: 38367045
Retatrutide showing promise in obesity (and type 2 diabetes). PMID: 37947489
Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes. PMID: 40583149
Retatrutide in type 2 diabetes mellitus and obesity: an overview. PMID: 41785010
Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. PMID: 37888927
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. PMID: 40685589
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. PMID: 38843460
?
?
?
詳情請咨詢 abinScience 亞洲區(qū)官方子公司 —— 武漢艾必賽生物技術(shù)有限公司
官方網(wǎng)址：【中文】https://www.abinscience.cn
【英文】https://www.abinscience.com
武漢艾必賽生物技術(shù)有限公司成立于 2023 年，是 abinScience 在亞洲地區(qū)設(shè)立的官方全資子公司，全面負(fù)責(zé) abinScience 品牌在亞太市場的科研試劑推廣、銷售及技術(shù)支持工作。
依托嚴(yán)格的產(chǎn)品研發(fā)體系和國際化的質(zhì)量管理標(biāo)準(zhǔn)，武漢艾必賽與 AtaGenix、ProteoGenix 等知名品牌保持長期戰(zhàn)略合作，現(xiàn)已構(gòu)建起涵蓋抗體、重組蛋白、工具酶、試劑盒、實(shí)驗(yàn)耗材在內(nèi)的多品類供應(yīng)體系，面向區(qū)域內(nèi)科研機(jī)構(gòu)、高校實(shí)驗(yàn)室與生物醫(yī)藥企業(yè)，提供穩(wěn)定、高效、可信賴的產(chǎn)品與服務(wù)。
核心業(yè)務(wù)覆蓋：
? 抗體產(chǎn)品（單抗、多抗、重組抗體等）
? 蛋白與多肽試劑（標(biāo)簽蛋白、功能蛋白等）
? 分子與細(xì)胞實(shí)驗(yàn)相關(guān)耗材
? 定制化研發(fā)服務(wù)（蛋白表達(dá)、抗體定制、親和力成熟等）
? 科研供應(yīng)鏈整合與項目配套支持
武漢艾必賽始終秉持“Empowering Bioscience Discovery”的理念，為亞太地區(qū)的生命科學(xué)研究持續(xù)注入高質(zhì)量動能。
?
?